Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SGC001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sungen’s SGC001 mAb Gets FDA Fast Track Approval as World-First Drug
Details : SGC001 is a monoclonal antibody, which is currently being evaluated for the treatment of patients suffering from acute myocardial infarction.
Product Name : SGC001
Product Type : Antibody
Upfront Cash : Inapplicable
March 24, 2025
Lead Product(s) : SGC001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable